Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | DDX3X | O00571 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552312 | 0.90 | CACNA1B (0.47) | IRAK4NPSR1 | |
| SCHEMBL25786437 | 0.85 | IRAK4 (0.43) | MAPK14IRAK4NPSR1 | |
| SCHEMBL20551922 | 0.83 | TRPM2 (0.41) | DHODHFPR2MAPTDDX3XABCG2 | |
| SCHEMBL20552711 | 0.83 | FLT1 (0.47) | FLT1KDR | |
| SCHEMBL20551791 | 0.83 | RAB9A (0.45) | DHODHFPR2MAPTPPARGNPSR1 | |
| SCHEMBL20552657 | 0.83 | JAK1 (0.43) | DHODHFPR2MAPT | |
| SCHEMBL20552417 | 0.81 | MAPT (0.55) | MAPTABCG2MAPK1NPSR1 | |
| SCHEMBL21749306 | 0.80 | FLT1 (0.46) | MAPK14FLT1KDRABCG2MDM2 | |
| SCHEMBL20552438 | 0.78 | SMN1; SMN2 (0.46) | DHODHFPR2MAPTPPARGNPSR1 | |
| SCHEMBL20552924 | 0.77 | KMT2A (0.43) | DHODHFPR2MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | MAPK14 2295/4885IRAK4 2748/4885DHODH 3053/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | MAPK14 2295/4885IRAK4 2748/4885DHODH 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.